9CD-99486-44247
2 vaccinations
3 coded responses
10 check-ins
3 free-text entries
1 call case
- Sex
- Male
- Age at first dose
- 66+
- ZIP prefix
- 331 / FL
- Registered
- 2021-01-07
- Relationship
- Self
- Race
- White
- Ethnicity
- N/A
Timeline
-
2020-12-17
Dose 1 — Pfizer-BioNTech
-
2021-01-07
Registered in v-safe
-
2021-01-07
Dose 2 — Pfizer-BioNTech
- 2021-01-09
- 2021-01-10
- 2021-01-11
-
2021-01-21
Survey response — day 14, dose 2MedDRA: Squamous cell carcinoma of lung, Unevaluable event — Feeling: Good · Get care from a doctor or other healthcare professionalFree text: Symptoms: Diagnosed last week with squamous cell lung cancer. · Healthcare visit (other): Staging studies. Meet Med. Oncolgy. & Rad. Oncol. Tomorrow.MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
-
2021-01-21
Report sent to call center — day 14, dose 2Get care from a doctor or other healthcare professional1 call case(s)
- 2021-01-28
- 2021-02-04
-
2021-02-11
Survey response — day 35, dose 2MedDRA: Dyspnoea, Hospitalisation, Pre-existing disease — Feeling: Fair · Be unable to workFree text: Increased.shortness of breath. Admitted to hospital. New left lower lobe infiltrate (where my lung cancer is. Sputum with light growth of MRSA. On iv vancomycin. Also 80 mg prednisone for possible idiosyncratic effect of Keytruda,MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
- 2021-02-18
- 2021-03-29
-
2021-04-08
Survey response — 3 months, dose 2MedDRA: Fatigue — Feeling: Poor · Be unable to work or attend school, Be unable to do your normal daily activitiesFree text: Severe tiredness, slept virtuallly all day but had f I'mll chemotherapy yesterday.MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
- 2021-07-08
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2020-12-17 | Pfizer-BioNTech | |
| 2 | 2021-01-07 | Pfizer-BioNTech |
Call center
1 call center case
1 unsuccessful
Free text
Release 2 — day 14, dose 2
Symptoms: Diagnosed last week with squamous cell lung cancer.
Healthcare visit (other): Staging studies. Meet Med. Oncolgy. & Rad. Oncol. Tomorrow.
Release 4 — day 35, dose 2
Symptoms: Increased.shortness of breath. Admitted to hospital. New left lower lobe infiltrate (where my lung cancer is. Sputum with light growth of MRSA. On iv vancomycin. Also 80 mg prednisone for possible idiosyncratic effect of Keytruda,
Release 7 — 3 months, dose 2
Symptoms: Severe tiredness, slept virtuallly all day but had f I'mll chemotherapy yesterday.
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| HCVO | Unevaluable event | ✓ | ✓ | ✓ |
| SD | Dyspnoea | ✓ | ✓ | ✓ |
| SD | Fatigue | ✓ | ✓ | ✓ |
| SD | Hospitalisation | ✓ | ✓ | ✓ |
| SD | Pre-existing disease | ✓ | ✓ | ✓ |
| SD | Squamous cell carcinoma of lung | ✓ | ✓ | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release